CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) +1 moredrug
Likely dose
triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00635258
NCT00635258N/ACompleted
CompareCT.gov

Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.

Centro Ginecologia y Obstetricia.·observational·Posted Mar 13, 2008·Updated Mar 13, 2008

In Brief

An observational study evaluating triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) and GnRH antagonist (Orgalutran®) for Pregnancy and Embryo Implantation. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPregnancy, Embryo Implantation
CountriesSpain
CollaboratorsUniversity of Valencia

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2008
Enrollment StartJan 1, 2004
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago

Interventions

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)drug

0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.

GnRH antagonist (Orgalutran®)drug

GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.